Development of therapeutic antibodies for the treatment of diseases

It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved. Current antibody drugs have increasingly fewer adverse effects due to their high specificity. As a result, therapeutic antibodies have become the predominant class of new drugs developed in recent years. Over the past five years, antibodies have become the best-selling drugs in the pharmaceutical market, and in 2018, eight of the top ten bestselling drugs worldwide were biologics. The global therapeutic monoclonal antibody market was valued at approximately US$115.2 billion in 2018 and is…

• AS
  Academia Sinica

  Awards: 106-0210-01-15-02, 107-0210-01-19-01
• MO
  Ministry of Science and Technology, Taiwan

  Awards: 107-0210-01-19-04, 107-0210-01-19-01, 106-0210-01-15-02